Glossary of biology

10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting

Retrieved on: 
Monday, February 5, 2024

PLEASANTON, Calif., Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Florida.

Key Points: 
  • "The new products we have planned for 2024 will take 10x to the next level, as we deliver game-changing new technologies that will redefine the Visium, Xenium and Chromium platforms," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics.
  • 10x Genomics will host a workshop at AGBT on Wednesday, February 7, at 1:10 p.m.
  • At AGBT, 10x Genomics will unveil new products, features and protocols designed to enable researchers with improved and more cost effective single cell workflows.
  • Throughout AGBT, 10x Genomics will demonstrate the use of its platforms to generate groundbreaking biological insights:
    Sponsor Workshop: Mind blowing science enabled by industry-leading single cell & spatial technologies (February 7, 2024).

The Paul G. Allen Family Foundation awards $10.5 million to new Allen Distinguished Investigators

Retrieved on: 
Tuesday, November 21, 2023

18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology

Key Points: 
  • 18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology
    The Paul G. Allen Family Foundation will award $1.5 million to seven research projects which 18 researchers will lead.
  • "Our two newest cohorts of Allen Distinguished Investigators are using innovative technologies and unprecedented ambition to pioneer new frontiers in the fields of sex hormones and extracellular vesicles.
  • said Kathy Richmond , Ph.D., M.B.A., Executive Vice President and Director of the Frontiers Group and the Office of Science and Innovation at the Allen Institute.
  • Including the new awards, a total of 130 Allen Distinguished Investigators have been appointed during the past 12 years.

Biological Dynamics Announces Early Access Program to Its ExoVerita™ Pro Platform

Retrieved on: 
Wednesday, November 8, 2023

Biological Dynamics, Inc. , the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.

Key Points: 
  • Biological Dynamics, Inc. , the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.
  • “Technology is revolutionizing our understanding and management of some of our most challenging diseases,” said Paul R. Billings, M.D., Ph.D., CEO and Director of Biological Dynamics.
  • Biological Dynamics’ ExoVerita technology platform offers an automated workflow for successfully detecting and recovering exosomes that have benefits over other methods, such as ultracentrifugation and column purification.
  • Biological Dynamics will showcase its Early Access Program and products at the Association for Molecular Pathology (AMP) Annual Meeting in Salt Lake City, Utah, Nov. 14-18, and will debut ExoVerita Pro at the SelectBio Conference in Laguna Hills, Calif., Nov. 28-30.

Labroots Announces Agenda for its 7th Annual Cell Biology Virtual Event Series on September 20, 2023

Retrieved on: 
Thursday, September 14, 2023

YORBA LINDA, Calif., Sept. 14, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual Cell Biology event convening on September 20, 2023. The online event is a unique meeting gathering thousands of cell biologists, scientists, research scholars, and experts from leading academia and industry institutions on a global basis. The impactful agenda will focus on the fundamental basis of cell biology and track sessions on translational and quantitative cell biology, exosomes, spatial omics, and Organ-On-A-Chip Technologies.

Key Points: 
  • YORBA LINDA, Calif., Sept. 14, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual Cell Biology event convening on September 20, 2023.
  • The impactful agenda will focus on the fundamental basis of cell biology and track sessions on translational and quantitative cell biology, exosomes, spatial omics, and Organ-On-A-Chip Technologies.
  • Join the online conversation and use the hashtag #LRcellbio and connect with other members of the global Cell & Molecular Biology community.
  • Follow @CellBiology_LR on Twitter and @CellandMolecularBiology.LR on Facebook to connect with our specialist Cell & Molecular Biology Writers and stay up to date with the latest Trending News in Cell & Molecular Biology.

New Study Demonstrates Efficient Exosome Isolation from Biological Fluids Using Proprietary Technology from Biological Dynamics

Retrieved on: 
Wednesday, July 26, 2023

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “ Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.

Key Points: 
  • Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “ Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.
  • ” The collaborative research with Oregon Health & Science University (OHSU) sheds light on the phenomenon occurring on Biological Dynamics’ ExoVerita platform that allows for the capture of biomarkers carried by nanoscale particles.
  • Biological Dynamics’ proprietary lab-on-a-chip platform leverages AC Electrokinetics (ACE) technology for the isolation of exosomes from undiluted biofluids, such as whole blood, plasma, and serum.
  • "I look forward to seeing how the advancements we make with the technique improve the capability of diagnostic tools to detect and analyze diseases."

aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)

Retrieved on: 
Tuesday, June 6, 2023

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada.

Key Points: 
  • Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading research in tRNA synthetase biology.
  • Presentations showcase company’s progress in generating new therapeutics from tRNA synthetase platform.
  • “As a leader in the field of tRNA biology, we look forward to highlighting some of the recent findings from our platform at AARS 2023,” said Leslie A. Nangle, Ph.D., Vice President, Research at aTyr.
  • aTyr is focused on elucidating novel pathways mediated through extracellular tRNA synthetases and creating new biologics to modulate these pathways by developing protein therapies based on extracellular tRNA synthetase fragments.

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Retrieved on: 
Wednesday, March 15, 2023

✓ the potential of Transgene’s novel cancer vaccines and oncolytic viruses to change the solid tumor treatment landscape in challenging clinical settings, and

Key Points: 
  • ✓ the potential of Transgene’s novel cancer vaccines and oncolytic viruses to change the solid tumor treatment landscape in challenging clinical settings, and
    ✓ the advances that Transgene has made with its two technology platforms.
  • Title: Extracellular vesicles (EV): mediators of therapeutic vaccination?
  • In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses
    Session title: Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory TherapiesPoster and abstract number: 697
    Date and Time Sunday Apr 16, 2023; 1:30 p.m. - 5:00 p.m.
  • ET
    In addition to presenting these posters, Transgene will also be hosting a booth during the AACR congress.

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

Retrieved on: 
Thursday, November 17, 2022

Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.

Key Points: 
  • Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.
  • "The addition of the TXP1 brain shuttle has the potential to significantly improve CNS penetration and efficacy.
  • The latest preclinical data for AT-04 demonstrate potent binding to multiple types of amyloid, as well as A, tau, and -synuclein fibrils in neurodegenerative disorders.
  • Ossianix brain shuttle platform is based on single domain VNAR antibodies and TXP1 is the most advanced brain shuttle ready for clinical translation.

United States Liquid Biopsy Market Report 2022: Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022

The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.
  • The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer.
  • The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services.

Big Idea Ventures’ latest cohort of startups enable scale and commercialization for the alternative protein industry

Retrieved on: 
Tuesday, October 4, 2022

Big Idea Ventures, global leader in early-stage investments in the alternative protein sector, revealed its latest accelerator cohort today.

Key Points: 
  • Big Idea Ventures, global leader in early-stage investments in the alternative protein sector, revealed its latest accelerator cohort today.
  • Seventeen early-stage startups were selected for pre-seed investment as part of Big Idea Ventures bi-annual new protein accelerator program.
  • The 17 companies in our latest cohort are all working to solve key challenges in the alternative protein industry today.
  • For more visit www.bigideaventures.com
    With the New Protein Fund, Big Idea Ventures invests in the best plant-based, cell-based and fermentation-enabled food, ingredient and technology companies.